145 related articles for article (PubMed ID: 31498561)
1. Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDS.
Barreau S; Green AS; Dussiau C; Alary AS; Raimbault A; Mathis S; Willems L; Bouscary D; Kosmider O; Bardet V; Fontenay M; Chapuis N
Cytometry B Clin Cytom; 2020 May; 98(3):226-237. PubMed ID: 31498561
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes.
Cherian S; Moore J; Bantly A; Vergilio JA; Klein P; Luger S; Bagg A
Cytometry B Clin Cytom; 2005 Mar; 64(1):9-17. PubMed ID: 15668954
[TBL] [Abstract][Full Text] [Related]
3. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.
Porwit A; Béné MC; Duetz C; Matarraz S; Oelschlaegel U; Westers TM; Wagner-Ballon O; Kordasti S; Valent P; Preijers F; Alhan C; Bellos F; Bettelheim P; Burbury K; Chapuis N; Cremers E; Della Porta MG; Dunlop A; Eidenschink-Brodersen L; Font P; Fontenay M; Hobo W; Ireland R; Johansson U; Loken MR; Ogata K; Orfao A; Psarra K; Saft L; Subira D; Te Marvelde J; Wells DA; van der Velden VHJ; Kern W; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Jan; 104(1):27-50. PubMed ID: 36537621
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.
Dhingra G; Dass J; Arya V; Gupta N; Saraf A; Langer S; Aggarwal S; Kotwal J; Bhargava M
Indian J Med Res; 2020 Sep; 152(3):254-262. PubMed ID: 33107485
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of the lymphoid screening tube supplemented with CD34 for Ogata score calculation in patients with peripheral cytopenia.
Muyldermans A; Florin L; Devos H; Cauwelier B; Emmerechts J
Hematology; 2019 Dec; 24(1):166-172. PubMed ID: 30334700
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.
Mathis S; Chapuis N; Debord C; Rouquette A; Radford-Weiss I; Park S; Dreyfus F; Lacombe C; Béné MC; Kosmider O; Fontenay M; Bardet V
Leukemia; 2013 Oct; 27(10):1981-7. PubMed ID: 23765225
[TBL] [Abstract][Full Text] [Related]
9. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.
Kern W; Bacher U; Haferlach C; Alpermann T; Schnittger S; Haferlach T
Cytometry B Clin Cytom; 2015; 88(3):154-64. PubMed ID: 25581461
[TBL] [Abstract][Full Text] [Related]
10. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
[TBL] [Abstract][Full Text] [Related]
11. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.
Bellos F; Alpermann T; Gouberman E; Haferlach C; Schnittger S; Haferlach T; Kern W
Cytometry B Clin Cytom; 2012 Sep; 82(5):295-304. PubMed ID: 22508616
[TBL] [Abstract][Full Text] [Related]
13. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
Kern W; Haferlach C; Schnittger S; Haferlach T
Cancer; 2010 Oct; 116(19):4549-63. PubMed ID: 20572043
[TBL] [Abstract][Full Text] [Related]
15. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndrome: validation of flow cytometry multilineage score system.
Araújo HV; Correia RP; Bento LC; Vaz ADC; Sousa FA; Alexandre AM; Schimidell D; Pedro EC; Ioshida MR; Barroso RS; Bacal NS
Einstein (Sao Paulo); 2020; 18():eAO4966. PubMed ID: 31994605
[TBL] [Abstract][Full Text] [Related]
17. Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry.
Clichet V; Lebon D; Chapuis N; Zhu J; Bardet V; Marolleau JP; Garçon L; Caulier A; Boyer T
Haematologica; 2023 Sep; 108(9):2435-2443. PubMed ID: 36924240
[TBL] [Abstract][Full Text] [Related]
18. A single-tube flow cytometric procedure for enhancing the diagnosis and prognostic classification of patients with myelodysplastic syndromes.
Kárai B; Bedekovics J; Miltényi Z; Gergely L; Szerafin L; Ujfalusi A; Kappelmayer J; Hevessy Z
Int J Lab Hematol; 2017 Dec; 39(6):577-584. PubMed ID: 28625017
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes.
Gardikas N; Vikentiou M; Konsta E; Kontos CK; Papageorgiou SG; Spathis A; Bazani E; Bouchla A; Kapsimali V; Psarra K; Foukas P; Dimitriadis G; Pappa V
Cytometry B Clin Cytom; 2019 Jan; 96(1):73-82. PubMed ID: 30334347
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
